ABSTRACT
No disponible
Subject(s)
Humans , Pharmacogenetics/methods , /genetics , Clinical Trials as Topic , Age Factors , Genetic Predisposition to Disease , Risk FactorsABSTRACT
No disponible
Subject(s)
Humans , Pharmacogenetics/methods , /genetics , Clinical Trials as Topic , Age Factors , Genetic Predisposition to Disease , Risk FactorsSubject(s)
Clinical Trials as Topic/methods , Pharmacogenetics/trends , Clinical Trials as Topic/statistics & numerical data , Clinical Trials as Topic/trends , Ethics Committees, Research , Humans , Multicenter Studies as Topic/statistics & numerical data , Multicenter Studies as Topic/trends , Pharmacogenetics/statistics & numerical data , Research Support as Topic/statistics & numerical data , Research Support as Topic/trends , Retrospective Studies , SpainABSTRACT
UNLABELLED: Intravenous immunoglobulin (IVIG) use in non-approved indications, the increase in consumption and its high cost recommend rationalisation in its utilisation. AIMS: To assess the use of IVIG in Spanish hospitals. METHODS: An observational, prospective and multicentre drug utilisation study was conducted in 13 tertiary Spanish hospitals. Data were collected for 3 months in patients receiving any IVIG. Patient demographics, indication for IVIG use, dosage regimen and cost of treatment were collected. RESULTS: Five hundred and fifty-four patients (mean age of 52 years) were included in the study. A total of 1,287 prescriptions were administered, and the average number of prescriptions per patient was 2.3. The mean daily dose was 24 g (range 0.6-90 g). Overall, IVIG was prescribed for authorised indications in 335 patients (60%) with 953 prescriptions (74%), for non-authorised indications with scientific evidentiary support in 86 patients (16%) with 137 prescriptions (11%), and non-authorised and non-accepted indications in 133 patients (24%) with 197 prescriptions (15%). The most frequent authorised indications were primary and secondary immunodeficiencies, and the most frequent non-authorised and non-accepted indications were multiple sclerosis and bullous dermatosis. The mean cost of IVIG per patient for authorised indications was 2,636.2
Subject(s)
Drug Costs , Drug Utilization/statistics & numerical data , Hospitals, General/statistics & numerical data , Immunoglobulins, Intravenous/economics , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/economics , Immunologic Factors/therapeutic use , Off-Label Use/statistics & numerical data , Adult , Aged , Drug Utilization/standards , Empathy , Female , Humans , Immunoglobulins, Intravenous/administration & dosage , Immunoglobulins, Intravenous/adverse effects , Immunologic Factors/administration & dosage , Immunologic Factors/adverse effects , Male , Middle Aged , Prospective Studies , SpainABSTRACT
La investigación biomédica mediante ensayos clínicos ofrece rasgos propios: finalidad concreta, aplicabilidad inmediata y efectuarse sobre seres humanos. Está sometida al ordenamiento jurídico, y en nuestro país específicamente al Real Decreto 223/2.004. Se puede definir al ensayo clínico como una prueba científica de un fármaco, aceptada por el enfermo y amparada por la ley. En cualquier caso, siempre deben respetárselos postulados éticos básicos: autonomía, justicia, beneficencia y no maleficencia. Los protagonistas den ensayo clínico son: promotor, monitor, investigador los sujetos del ensayo, todos ellos ensamblados porras autoridades sanitarias. Para su aprobación, el ensayo clínico necesita la existencia de un protocolo específico. El principal problema en la realización reensayos clínicos es conseguir la coordinación de todas las personas e instituciones participantes en el mismo (AU)
Biomedical research via clinical trials offers certain features: defined aim, immediate applicability, and implementation on human beings. It is subject to the legal system in Spain, specifically to the Real Decreto 223/2.004. The clinical trial can be defined as the scientific testing of a drug, accepted by the patient and safeguarded by law. In all cases, the basic ethical postulates of independence, equity, virtue, and non-harmfulness must always be respected. The participants in a clinical trial are the promoter, the supervisor, the researcher, and the subjects under trial all convened by the health authorities. The approval of a clinical trial requires the existence of a specific protocol. The main problem in carrying out clinical trials is to achieve the co-ordination of all the people and institutions taking part (AU)
Subject(s)
Humans , Therapeutics/methods , Therapeutic Human Experimentation , Drugs, Investigational , Clinical Trials as Topic , Drug Evaluation/ethics , Clinical ProtocolsABSTRACT
No disponible
